Open AccessMucor Mycosis in COVID-19: Case Reports
Author(s) -
Ranjana Deshmukh,
Kavita Upadhyay,
Ravindra S. Patwadkar,
Shridhan Patil
Publication year - 2020
Publication title -
journal of advanced research in medicine
Language(s) - English
Resource type - Journals
eISSN - 2394-7047
pISSN - 2349-7181
DOI - 10.24321/2349.7181.202016
Subject(s) - mucormycosis , covid-19 , pathogenesis , monoclonal antibody , microbiology and biotechnology , immunology , mucor , antibiotics , coronavirus , broad spectrum , biology , disease , medicine , virology , antibody , pathology , outbreak , infectious disease (medical specialty) , chemistry , aspergillus , combinatorial chemistry
Coronavirus infections are associated with a wide range of bacterial and fungal co-infections. Use of steroids, monoclonal antibodies and broad spectrum antibiotics along with underlying pathogenesis may alter body homeostasis and exacerbate preexisting fungal disease. We report the cases with COVID-19 infection, which, after the course of the treatment, presented with various forms of mucormycosis infection.